ORIDONIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C20H28O6
Molecular Weight	364.4327
Optical Activity	UNSPECIFIED
Defined Stereocenters	9 / 9
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]12CC[C@]3([H])[C@@]([C@@H]1O)(C(=O)C2=C)[C@]4(O)OC[C@]35[C@@H](O)CCC(C)(C)[C@@]5([H])[C@@H]4O

InChI

InChIKey=SDHTXBWLVGWJFT-XKCURVIJSA-N

InChI=1S/C20H28O6/c1-9-10-4-5-11-18-8-26-20(25,19(11,14(9)22)15(10)23)16(24)13(18)17(2,3)7-6-12(18)21/h10-13,15-16,21,23-25H,1,4-8H2,2-3H3/t10-,11-,12-,13+,15+,16-,18+,19-,20+/m0/s1

HIDE SMILES / InChI

Molecular Formula	C20H28O6
Molecular Weight	364.4327
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	9 / 9
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27344488 | https://www.ncbi.nlm.nih.gov/pubmed/16432862

Oridonin is a diterpenoid purified from Rabdosia rubescens. In traditional Chinese medicine oridonin powder (Donglingcao herb extract) is used as an over-the-counter medicine because of its anti-tumor, anti-bacterial, anti-inflammatory, analgesic and other effects. Oridonin was shown to inhibit many tumor cell lines in vitro and its mechanism of action is mainly explained by inhibition of NF-kB signaling, Keap1-Nrf2-ARE pathway and upregulation of p53/p21 signaling and ROS production.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
NF-kappa B signaling pathway 84 Target ID: map04064 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25121593	Inhibitor 8297
Oxidative Stress 160 Target ID: WP408 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27344488	Activator 1430
Transcriptional activation by NRF2 1 Target ID: WP3 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27344488	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Acute myeloid leukemia 136 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27344488	Primary		Preclinical	Unknown Approved Use Unknown
Chronic myeloid leukemia 25 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27344488	Primary		Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Apoptotic effect of oridonin on NB4 cells and its mechanism.	2005 Apr	16019488
Oridonin promotes CD4+/CD25+ Treg differentiation, modulates Th1/Th2 balance and induces HO-1 in rat splenic lymphocytes.	2008 Apr	18351433
Interaction of oridonin with human serum albumin by isothermal titration calorimetry and spectroscopic techniques.	2015 May 5	25816984
Inhibition of RNA transportation induces glioma cell apoptosis via downregulation of RanGAP1 expression.	2015 May 5	25746355

Patents

Sample Use Guides

In Vivo Use Guide

Oridonin inhibits tumor growth in K562 xenograft nude mice at dose 10 and 15 mg/kg.

Route of Administration: Intraperitoneal

In Vitro Use Guide

SGC996 and NOZ cells were treated with oridonin (0.75, 1.5, and 3 μmol/L) and were allowed to form colonies in fresh medium for 14 days. Oridonin completely inhibited cells prolifiration at 30 uM.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 01:53:41 GMT 2023` Edited by `admin` on `Sat Dec 16 01:53:41 GMT 2023`
Record UNII	0APJ98UCLQ
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ORIDONIN

Official Name

English

ORIDONIN [INCI]

Common Name

English

PURE ORIDONIN

Brand Name

English

ORIDONINE

Common Name

English

KAUR-16-EN-15-ONE, 7.ALPHA.,20-EPOXY-1.ALPHA.,6.BETA.,7,14-TETRAHYDROXY-, (14R)-

Common Name

English

ISODONOL

Common Name

English

NSC-250682

Code

English

KAUR-16-EN-15-ONE, 7,20-EPOXY-1,6,7,14-TETRAHYDROXY-, (1.ALPHA.,6.BETA.,7.ALPHA.,14R)-

Common Name

English

Code System Code Type Description

PUBCHEM

5321010